甘李药业
(603087)
| 流通市值：258.35亿 | | | 总市值：280.34亿 |
| 流通股本：5.54亿 | | | 总股本：6.01亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,245,006,087.12 | 1,314,892,845.25 | 560,334,209.7 | 2,608,036,951.05 |
| 营业收入 | 2,245,006,087.12 | 1,314,892,845.25 | 560,334,209.7 | 2,608,036,951.05 |
| 二、营业总成本 | 1,921,772,067.24 | 1,182,053,775.74 | 541,954,966.18 | 2,306,681,448.38 |
| 营业成本 | 553,241,458.86 | 349,098,771 | 152,249,465.95 | 697,421,415.19 |
| 税金及附加 | 22,246,574.82 | 14,438,685.7 | 6,264,933.61 | 24,262,877.27 |
| 销售费用 | 831,334,688.22 | 490,979,157.99 | 227,086,625 | 945,947,681.96 |
| 管理费用 | 169,962,996.5 | 102,698,124.09 | 43,299,233.12 | 216,749,734.43 |
| 研发费用 | 403,442,931.89 | 266,476,949.6 | 133,120,155.74 | 501,022,439.64 |
| 财务费用 | -58,456,583.05 | -41,637,912.64 | -20,065,447.24 | -78,722,700.11 |
| 其中:利息费用 | - | - | - | 551,702.82 |
| 其中:利息收入 | - | - | - | 77,675,363.58 |
| 加:公允价值变动收益 | 167,902,884.11 | 154,127,142.24 | 85,501,251.91 | -17,916,475.02 |
| 加:投资收益 | 55,851,319.43 | 41,403,196.59 | 2,265,318.1 | 63,331,043.01 |
| 资产处置收益 | 658,001.36 | 563,341.74 | 580,914.39 | 339,265.71 |
| 资产减值损失(新) | 16,817.47 | 16,817.47 | 49,622.31 | -39,827,886.2 |
| 信用减值损失(新) | 529,401.96 | 961,325.19 | - | -15,964,110.46 |
| 其他收益 | 14,065,608.78 | 9,438,127.54 | 6,339,484.78 | 23,968,646.18 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 562,258,052.99 | 339,349,020.28 | 113,115,835.01 | 315,285,985.89 |
| 加:营业外收入 | 2,164,705.3 | 1,794,212.53 | 519,781.04 | 4,122,559.53 |
| 减:营业外支出 | 818,059.37 | 290,700.18 | 75,272.07 | 13,267,468.18 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 563,604,698.92 | 340,852,532.63 | 113,560,343.98 | 306,141,077.24 |
| 减:所得税费用 | 56,339,499.4 | 41,948,483.73 | 17,556,110.25 | -34,090,412.95 |
| 六、净利润 | 507,265,199.52 | 298,904,048.9 | 96,004,233.73 | 340,231,490.19 |
| 持续经营净利润 | 507,265,199.52 | 298,904,048.9 | 96,004,233.73 | 340,231,490.19 |
| 归属于母公司股东的净利润 | 507,265,245.69 | 298,904,095.07 | 96,004,278.2 | 340,068,569.84 |
| 少数股东损益 | -46.17 | -46.17 | -44.47 | 162,920.35 |
| (一)基本每股收益 | 0.85 | 0.51 | 0.16 | 0.6 |
| (二)稀释每股收益 | 0.85 | 0.51 | 0.16 | 0.6 |
| 八、其他综合收益 | -865,256.02 | -138,136.72 | -110,985.06 | 375,299.98 |
| 归属于母公司股东的其他综合收益 | -865,256.02 | -138,136.72 | -110,985.06 | 375,299.98 |
| 九、综合收益总额 | 506,399,943.5 | 298,765,912.18 | 95,893,248.67 | 340,606,790.17 |
| 归属于母公司股东的综合收益总额 | 506,399,989.67 | 298,765,958.35 | 95,893,293.14 | 340,443,869.82 |
| 归属于少数股东的综合收益总额 | -46.17 | -46.17 | -44.47 | 162,920.35 |
| 公告日期 | 2024-10-23 | 2024-08-29 | 2024-04-25 | 2024-04-25 |
| 审计意见(境内) | | | | 标准无保留意见 |